Intervention Protocol

Antifungal agents for the treatment of mucocutaneous candidiasis in neonates and children

  1. Peter H Gray1,*,
  2. Clare B Nourse2,
  3. Alison Peeler3

Editorial Group: Cochrane Neonatal Group

Published Online: 19 JUL 2004

Assessed as up-to-date: 11 MAY 2004

DOI: 10.1002/14651858.CD004867

How to Cite

Gray PH, Nourse CB, Peeler A. Antifungal agents for the treatment of mucocutaneous candidiasis in neonates and children (Protocol). Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD004867. DOI: 10.1002/14651858.CD004867.

Author Information

  1. 1

    University of Queensland, Neonatology, South Brisbane, Queensland, Australia

  2. 2

    Mater Children's Hospital, Paediatrics, South Brisbane, Queensland, Australia

  3. 3

    Mater Mothers' Hospital, Neonatology, South Brisbane, Queensland, Australia

*Peter H Gray, Neonatology, University of Queensland, Mater Mothers' Hospital, Raymond Tce, South Brisbane, Queensland, 4101, Australia. Peter_Gray@mater.org.au.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 19 JUL 2004

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

1. In newborn infants and children, to assess the effectiveness of different antifungal agents for the treatment of oral candidiasis with respect to clinical and mycologic cure. Separate comparisons of the following antifungal agents - gentian violet, nystatin, amphotericin B, miconazole, clotrimazole, ketoconazole and fluconazole - will be undertaken. Each will be compared with placebo and with each other agent.

2. In newborn infants and children, to assess the effectiveness of different antifungal agents for the treatment of Candida infections of the skin with respect to clinical cure and mycologic cure. Separate comparisons of the following antifungal agents - gentian violet, nystatin, amphotericin B, miconazole, clotrimazole, tioconazole, ketoconazole, fluconazole, tolciclate, haloprogin and mupirocin - will be undertaken.

Each will be compared with placebo and each other agent.

Secondary outcomes investigated will include rates of relapse and adverse effects of antifungal drugs.

Planned subgroup analyses will include:
1. Therapy for cutaneous Candida infections with and without concurrent oral antifungal therapy
2. Children <1 year of age
3. Newborn infants <28 days old
4. Healthy children without concomitant illness and not in receipt of concurrent systemic antimicrobial therapy